Real-World Utilization of Target- and Immunotherapies for Lung Cancer: A Scoping Review of Studies Based on Routinely Collected Electronic Healthcare Data

Andrea Spini, Giulia Hyeraci, Claudia Bartolini, Sandra Donnini, Pietro Rosellini, Rosa Gini, Marina Ziche, Francesco Salvo and Giuseppe Roberto
Additional contact information
Andrea Spini: INSERM, BPH, U1219, Team Pharmacoepidemiology, University of Bordeaux, 33000 Bordeaux, France
Giulia Hyeraci: Osservatorio di Epidemiologia, Agenzia Regionale di Sanità Della Toscana, 50141 Florence, Italy
Claudia Bartolini: Osservatorio di Epidemiologia, Agenzia Regionale di Sanità Della Toscana, 50141 Florence, Italy
Sandra Donnini: Department of Life Sciences, University of Siena, 53100 Siena, Italy
Pietro Rosellini: CIC1401, CIC Bordeaux, 33000 Bordeaux, France
Rosa Gini: Osservatorio di Epidemiologia, Agenzia Regionale di Sanità Della Toscana, 50141 Florence, Italy
Marina Ziche: Department of Medical Science, Surgery and Neuroscience, University of Siena, 53100 Siena, Italy
Francesco Salvo: INSERM, BPH, U1219, Team Pharmacoepidemiology, University of Bordeaux, 33000 Bordeaux, France
Giuseppe Roberto: Osservatorio di Epidemiologia, Agenzia Regionale di Sanità Della Toscana, 50141 Florence, Italy

IJERPH, 2021, vol. 18, issue 14, 1-21

Abstract: Routinely collected electronic healthcare data (rcEHD) have a tremendous potential for enriching pre-marketing evidence on target- and immunotherapies used to treat lung cancer (LC). A scoping review was performed to provide a structured overview of available rcEHD-based studies on this topic and to support the execution of future research by facilitating access to pertinent literature both for study design and benchmarking. Eligible studies published between 2016 and 2020 in PubMed and ISI Web of Science were searched. Data source and study characteristics, as well as evidence on drug utilization and survival were extracted. Thirty-two studies were included. Twenty-six studies used North American data, while three used European data only. Thirteen studies linked ?1 data source types among administrative/claims data, cancer registries and medical/health records. Twenty-nine studies retrieved cancer-related information from medical records/cancer registries and 31 studies retrieved information on drug utilization or survival from medical records or administrative/claim data. Most part of studies concerned non-small-cell-LC patients (29 out of 32) while none focused on small-cell-LC. Study cohorts ranged between 85 to 81,983 patients. Only two studies described first-line utilization of immunotherapies. Results from this review will serve as a starting point for the execution of future rcEHD-based studies on innovative LC pharmacotherapies.

Keywords: electronic healthcare data; big data; real-word data; real-word evidence; drug utilization; lung cancer; immunotherapy; target-therapy; scoping review (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2021
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/18/14/7679/pdf (application/pdf)
https://www.mdpi.com/1660-4601/18/14/7679/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:18:y:2021:i:14:p:7679-:d:597307

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().